Gbola Amusa
Stock Analyst at Chardan Capital
(1.24)
# 2,628
Out of 4,433 analysts
36
Total ratings
40.82%
Success rate
3.11%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $8.25 | +506.06% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | n/a | $3.14 | - | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | n/a | $0.63 | - | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | n/a | $9.30 | - | 3 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | n/a | $1.34 | - | 1 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | n/a | $0.92 | - | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | n/a | $5.07 | - | 2 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | n/a | $1.68 | - | 1 | Jan 13, 2021 | |
| IMVT Immunovant | Maintains: Buy | n/a | $31.48 | - | 3 | Aug 25, 2020 | |
| KRYS Krystal Biotech | Maintains: Buy | n/a | $163.78 | - | 1 | Aug 19, 2020 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | n/a | $10.43 | - | 2 | Aug 7, 2020 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | n/a | $55.67 | - | 1 | Jul 28, 2020 | |
| MRNA Moderna | Maintains: Buy | n/a | $132.68 | - | 2 | Jul 15, 2020 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | n/a | $9.50 | - | 1 | Aug 17, 2018 | |
| RGNX REGENXBIO | Maintains: Buy | n/a | $16.01 | - | 4 | Jul 16, 2018 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | n/a | $2.59 | - | 1 | Mar 27, 2018 | |
| AXON Axon Enterprise | Upgrades: Neutral | n/a | $290.44 | - | 1 | Jan 10, 2018 | |
| SAGE Sage Therapeutics | Upgrades: Buy | n/a | $12.01 | - | 1 | Nov 10, 2017 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Neutral | n/a | $967.98 | - | 1 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $8.25
Upside: +506.06%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: n/a
Current: $3.14
Upside: -
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: n/a
Current: $0.63
Upside: -
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: n/a
Current: $9.30
Upside: -
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: n/a
Current: $1.34
Upside: -
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: n/a
Current: $0.92
Upside: -
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: n/a
Current: $5.07
Upside: -
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: n/a
Current: $1.68
Upside: -
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: n/a
Current: $31.48
Upside: -
Krystal Biotech
Aug 19, 2020
Maintains: Buy
Price Target: n/a
Current: $163.78
Upside: -
Iovance Biotherapeutics
Aug 7, 2020
Maintains: Buy
Price Target: n/a
Current: $10.43
Upside: -
CRISPR Therapeutics AG
Jul 28, 2020
Maintains: Buy
Price Target: n/a
Current: $55.67
Upside: -
Moderna
Jul 15, 2020
Maintains: Buy
Price Target: n/a
Current: $132.68
Upside: -
Amicus Therapeutics
Aug 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $9.50
Upside: -
REGENXBIO
Jul 16, 2018
Maintains: Buy
Price Target: n/a
Current: $16.01
Upside: -
Esperion Therapeutics
Mar 27, 2018
Maintains: Neutral
Price Target: n/a
Current: $2.59
Upside: -
Axon Enterprise
Jan 10, 2018
Upgrades: Neutral
Price Target: n/a
Current: $290.44
Upside: -
Sage Therapeutics
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $12.01
Upside: -
Regeneron Pharmaceuticals
Dec 12, 2016
Upgrades: Neutral
Price Target: n/a
Current: $967.98
Upside: -